Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7272 p569
25 October 2003

This article
Reprint
Photocopy


News summary

Related websites
Better Regulation Task Force (www.brtf.gov.uk)


Implications for Society in better regulation report

Independent regulators should all have appeals mechanisms that allow affected parties to appeal against decisions before having to resort to judicial review, the Government's Better Regulation Task Force has said.

This recommendation, and others, might have implications for the Royal Pharmaceutical Society’s modernisation process because its current plans for reform of the profession’s disciplinary machinery allow for no appeals other than to the High Court and, in the case of a caution by the disciplinary committee, no appeal at all.

The task force’s latest report, on independent regulators, sets out five principles of good regulation — proportionality, accountability, consistency, transparency and targeting — which it wants to see implemented by all regulatory bodies, including the Royal Pharmaceutical Society and others that regulate professions.

The main target of the report is statutory regulators established by Act of Parliament, but the task force makes clear that any body that exerts powers over, or imposes burdens on, other organisations or individuals is a regulator which should take the report seriously. It says: “We recognise the independence of the regulators and hope that, as happened with the economic regulators, the most open-minded will respond quickly and the rest will follow suit. ... We expect all Departments to disseminate the report to their regulators and work with them to implement our recommendations.”

On appeals, the report says that independent regulators potentially wield enormous power and that those being regulated, and those on whose behalf regulation takes place, should be able to appeal against decision that substantially impact upon them. Appeals should be less costly and time consuming than a judicial review. Regulators fall largely into two groups, the task force says — those which have internal appeals and those where appeals are to a Secretary of State or though the courts. “The latter process may be too burdensome for some to use,” the report states.

The task force, set up by the Cabinet Office, also says that regulators should be run by management boards that have a majority of non-executive members, all of whom should ideally have no connection with the activity being regulated.

Other recommendations include the setting out of management statements that describe regulatory aims and how a regulator is held to account for its performance and adherence to Government standards for consultation and enforcement processes.

In all, the report makes 14 recommendations intended to achieve fairness and transparency in regulatory processes.

In a statement, the Society said: “The Council’s proposals [for reform] would put in place appropriate appeals mechanisms for the future, separate from any judicial review procedure.”

It added: “The Council’s proposals take account of the arrangements agreed in recent years for bodies regulating other health professions, legal advice and advice received from the Department of Health. We believe that they will form the basis of appropriate and proportionate procedures for the future.”

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal